GSKVX000000009151

GSKVX000000009151 is a viral vector vaccine candidate developed by GSK for the treatment of chronic hepatitis B (CHB). It utilizes the Chimpanzee Adenovirus 155 (ChAd155) platform to deliver genetic sequences encoding three essential hepatitis B virus (HBV) antigens: the surface antigen (HBsAg), the core antigen (HBcAg), and a truncated version of the viral polymerase. The vaccine is designed to stimulate a potent, multi-specific T-cell response aimed at clearing HBV-infected hepatocytes and achieving a "functional cure," defined as the sustained loss of HBsAg. In clinical trials, GSKVX000000009151 is typically evaluated as part of a heterologous prime-boost immunotherapy regimen (often referred to as GSK3903371) that includes an MVA-HBV viral vector vaccine and an adjuvanted protein vaccine (GSK3528869A).

Other names

Chimpanzee Adenovirus 155-HBVGSK HBV viral vector vaccine